Cisapride 가 고양이 변비에 사용될수있다. serotonergic 5-hydroxytryptamine receptor
4 (5-HT4) agonists. 근데 이건 못쓰는 나라가 많음. 대체제로 같은 5HT4 제재인 Mosapride 를 사용할수있다.
0.25~1 mg/kg, po, q 12hr.
부작용으로 QT interval 어쩌구 있는데, 14마리 고양이에서 발견된바 없었음.
5ht4ago 인 여러 약물이 있는데, 이건 colon 에 작용하지는 않음. 가령 metocloprimide 는 upper GIT 에 국한되어 작용함.
cisapride 는 용량 의존적으로 모든 장소에 작용할수있다. cisapride 의 prokinetic 효과는 간접적인 교감신경의 자극과 5ht4 수용체와의 상호작용을 반영햐는것으로 보인다. cisapride 는 칼슘 의존성 수축을 일으킨다.
(원문)
<<Use of Mosapride Citrate in Cats with Chronic Constipation>>
Constipation is a common disorder in cats. The use of intestinal prokinetic drugs such as cisapride, a serotonergic 5-hydroxytryptamine (5-HT4) receptor agonist, may be vital to managing the chronically constipated cat. However, cisapride was withdrawn from the market in a number of countries and is only available from compounding pharmacies. This retrospective study describes the use of another 5-HT4 receptor agonist, mosapride citrate, as monotherapy for cats with frequent episodes of constipation.
Fifteen cats were evaluated for straining to defecate and failure to pass stool for several days. A physical examination revealed dehydration and a firm fecal mass on abdominal palpation in all of the animals. On right lateral abdominal radiographs, moderate to severe dilation of the colon with impacted feces was seen. Each cat was given an enema, and standard of care medical management was prescribed. However, constipation recurred in all cats. To enhance colonic motility after the passage of feces, mosapride was administered orally at a dose of 5 mg per cat every 12 hours. While receiving mosapride alone, there was no recurrence of constipation in 14 of the cats. None of the animals experienced gastrointestinal adverse effects or prolongation of the QT interval on electrocardiogram.
Administration of mosapride as monotherapy appears to be an effective therapy for management of feline constipation or obstipation.
'약' 카테고리의 다른 글
풀미코트 (0) | 2023.05.02 |
---|---|
복합정장지사제 / 베르베린 / 부스코판/ 스코폴라민 (0) | 2023.04.19 |
네뷸 nebul 호흡기약물 (0) | 2023.04.07 |
리도카인, 베타블로커의 이용 (0) | 2023.03.01 |
앰플 (0) | 2023.02.17 |